DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Zepbound - 2 — - 1 ” Julie Flygare - 1 Susan Spratt - 1 ” Spratt - 1 Timothy Morgenthaler - 1 Phillips Respironics - 1
Top related locs:
Novo United States North Carolina Brooklyn New York U.S
Top related orgs:
Drug Administration - 2 Novo Nordisk - 2 FDA - 1 American Academy of - 1 Population Health Management - 1 Duke Health - 1 PAP - 1 Mayo Clinic - 1

Search resuls for: "Julie Flygare"


2 mentions found


☆ FDA approves weight loss drug Zepbound for sleep apnea
  + stars: | 2024-12-20 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms | Berkeley Lovelace Jr. | ) www.nbcnews.com   time to read: +5 min
The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The expanded approval could persuade more insurance companies — which have been reluctant to cover the expensive weight loss drugs — to pay for the medication. Obstructive sleep apnea occurs when the upper airway becomes blocked during sleep, cutting off airflow throughout the night. The approval is based on two trials of men and women with obesity and moderate to severe sleep apnea. Other sleep apnea treatmentsMany people who have sleep apnea go undiagnosed and untreated.
Persons: Eli Lilly, —, ” Julie Flygare, Zepbound, Susan Spratt, ” Spratt, Timothy Morgenthaler, Phillips Respironics, Morgenthaler, tirzepatide, ” Morgenthaler, Lilly, ” Organizations: Drug Administration, FDA, American Academy of, Novo Nordisk, Population Health Management, Duke Health, PAP, Mayo Clinic Locations: United States, Novo, North Carolina
☆ FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
  + stars: | 2024-12-20 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +4 min
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. The Food and Drug Administration approved Eli Lilly 's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, the drugmaker announced Friday, expanding its use and possibly its insurance coverage in the U.S. An estimated 80 million patients in the U.S. experience the disease, according to Eli Lilly. Eli Lilly expects to launch the drug for OSA at the beginning of next year. In June, Eli Lilly released additional data from the studies showing that Zepbound helpedresolve OSA in almost half of patients.
Persons: Eli Lilly, Julie Flygare, Zepbound Organizations: Drug Administration, U.S, CNBC, OSA, Novo Nordisk Locations: Brooklyn, New York, U.S, Novo
0 next >>
Total: 2